Posted from: Monday, March 02, 2015 - 05:26 PM - Present

Prezcobix Approved for HIV

The FDA approved Prezcobix (darunavir 800mg and cobicistat 150mg) tablets for use in combination with other antiretroviral agents for the treatment HIV-1 infection in adults. Prezcobix, manufactured by Jannsen is a fixed-dose, once-daily tablet that combines its protease inhibitor Prezist (darunavir) with Gilead’s Tybost. Jannsen plans on launching Prezcobix the first week in February.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

 

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

 

Last Updated Thursday, March 23, 2017 - 08:02 AM.